Lapatinib ( DrugBank: Lapatinib )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 2 |
| 74 | Prolactin secreting pituitary adenoma | 1 |
| 75 | Cushing disease | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00973739 (ClinicalTrials.gov) | September 2009 | 3/9/2009 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors | Neurofibromatosis 2;Vestibular Schwannoma | Drug: Lapatinib | New York University School of Medicine | GlaxoSmithKline | Completed | 4 Years | 80 Years | All | 21 | Phase 2 | United States |
| 2 | NCT00863122 (ClinicalTrials.gov) | June 2009 | 13/3/2009 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas | Vestibular Schwannoma;NF2;Neurofibromatosis 2;Acoustic Neuroma;Auditory Tumor | Drug: lapatinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The Children's Tumor Foundation;GlaxoSmithKline;New York University;Ohio State University;House Research Institute;Washington University School of Medicine;Weill Medical College of Cornell University;Massachusetts General Hospital | Completed | 18 Years | N/A | All | 26 | Early Phase 1 | United States |
74. Prolactin secreting pituitary adenoma
Clinical trials : 19 / Drugs : 28 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00939523 (ClinicalTrials.gov) | July 2009 | 14/7/2009 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Pituitary Adenomas;Prolactinomas | Drug: Lapatinib | Cedars-Sinai Medical Center | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |
75. Cushing disease
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-OPC-17011664 | 2017-08-01 | 2017-06-14 | A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease | A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease | Pituitary ACTH-secreting adenoma | Treatment group:lapatinib; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Treatment group:30; | China |